Description
Angivas MR 35 mg Tablet is a medication containing Trimetazidine Dihydrochloride, designed to manage stable angina pectoris in adults inadequately controlled by or intolerant to first-line antianginal therapies. By inhibiting the enzyme 3-keto acyl CoA thiolase, it shifts the heart's energy production from fatty acids to glucose, enhancing oxygen efficiency and reducing lactic acid accumulation, thereby alleviating angina symptoms. The recommended dosage is 35 mg twice daily or 20 mg three times daily during meals. Treatment efficacy should be assessed after three months, and discontinuation is advised if no improvement is observed. Common side effects include dizziness, headache, abdominal pain, nausea, vomiting, rash, and fatigue. Angivas MR is contraindicated in patients with hypersensitivity to Trimetazidine, Parkinson's disease, parkinsonian symptoms, tremors, restless legs syndrome, or severe renal impairment. It is not intended for the acute treatment of angina attacks or for use in unstable angina pectoris or myocardial infarction. During pregnancy and breastfeeding, its use is not recommended due to potential risks, and it should be used only if the potential benefits outweigh the risks. The tablet should be stored in a dry place, away from light and heat, and out of reach of children
.jpg)
Change Language